Magrath George sold 28,258 shares of Opus Genetics, Inc. at $3.90 for −$110k on Nov 3, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Chief Executive Officer
Chief Executive Officer
Filed Nov 5, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$110,183.59Shares × reported price
Shares traded
28,258Common Stock
Price per share
$3.90Reported price. Read footnotes for ranges.
% of reported position traded
1.39%This security and ownership context
Holdings after
2,010,636Direct
Trade date
Nov 3, 2026Sell
Filed
Nov 5, 2026, 4:04 PM ET2-day reporting delay
Accession
0001140361-26-042102Code S · Transaction 393346
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 2,038,894 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

IRD price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
IRD · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +14%1w ago −14%1d ago −7.5%
Returns since7d +7.5%30d90d180d1y

Footnotes in full

F1: The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Issuer to satisfy tax withholding obligations that arose in connection with the vesting and settlement of restricted stock units. This transaction does not represent a discretionary trade by the Reporting Person. F2: The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $3.89 to $3.935, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.